Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret<superscript>®</superscript>) Example
In: Infectious Diseases and Therapy, Jg. 13 (2024-03-01), Heft 3, S. 549-564
Online
academicJournal
Zugriff:
Titel: |
Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret<superscript>®</superscript>) Example
|
---|---|
Autor/in / Beteiligte Person: | Warren, Emma ; Castles, Belinda J. C. ; Sharratt, Gillian C. ; Arteaga, Aitor |
Link: | |
Zeitschrift: | Infectious Diseases and Therapy, Jg. 13 (2024-03-01), Heft 3, S. 549-564 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 2193-8229 (print) ; 2193-6382 (print) |
DOI: | 10.1007/s40121-024-00926-1 |
Sonstiges: |
|